Home > Boards > US Listed > Biotechs > Amarin Corp. PLC ADS (AMRN)

SocialBoom,We have actually spent little to no time

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
MedResCollab Member Profile
 
Followed By 2
Posts 211
Boards Moderated 0
Alias Born 01/18/19
160x600 placeholder
REDUCE-IT® Heart Failure Analyses by VASCEPA® (Icosapent Ethyl)-Driven Serum Eicosapentaenoic Acid (EPA) Levels Suggest Pot... GlobeNewswire Inc. - 5/15/2021 8:00:00 AM
Clinical Data and Other Research Results Regarding VASCEPA® (Icosapent Ethyl) and Its Unique Active Ingredient to Be Present... GlobeNewswire Inc. - 5/4/2021 7:00:00 AM
Amarin reports decline in Q1 revenue ahead of European launch of VAZKEPA Seeking Alpha - 4/29/2021 7:31:32 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 4/29/2021 6:36:55 AM
Amarin EPS beats by $0.07, misses on revenue Seeking Alpha - 4/29/2021 6:16:54 AM
Amarin Reports First Quarter 2021 Financial Results and Provides Business Update GlobeNewswire Inc. - 4/29/2021 6:10:00 AM
Amarin Announces Planned Retirement of Joseph T. Kennedy, EVP, General Counsel GlobeNewswire Inc. - 4/29/2021 6:00:00 AM
Amarin Q1 2021 Earnings Preview Seeking Alpha - 4/28/2021 1:06:54 PM
UK approves Amarin's Vazkepa for cardiovascular risk reduction Seeking Alpha - 4/22/2021 11:22:31 AM
Amarin Receives Great Britain Marketing Authorization for VAZKEPA from the Medicines and Healthcare Products Regulatory Agenc... GlobeNewswire Inc. - 4/22/2021 10:53:02 AM
Amarin to Report First Quarter Results and Host Conference Call on April 29, 2021 GlobeNewswire Inc. - 4/20/2021 6:05:00 AM
VASCEPA® (Icosapent Ethyl) Reported to Impact Vulnerable Coronary Plaque Features in New Analyses of EVAPORATE Study Present... GlobeNewswire Inc. - 4/17/2021 9:50:00 AM
Amarin: Could the New CEO Help Vazkepa’s European Push? TipRanks - 4/13/2021 3:05:37 PM
Amarin falls as new CEO may mean M&A less likely in the near term Seeking Alpha - 4/13/2021 8:08:18 AM
Amarin CEO John Thero to retire Seeking Alpha - 4/12/2021 4:36:21 PM
Amarin Announces CEO Succession Plan GlobeNewswire Inc. - 4/12/2021 4:30:00 PM
Amarin Commences Commercial Initiatives for VAZKEPA in European Union Following Recent Regulatory Approval for Cardiovascular... GlobeNewswire Inc. - 4/6/2021 6:05:00 AM
Amarin wins EU approval for icosapent ethyl to treat cardiovascular patients Seeking Alpha - 3/30/2021 7:42:41 AM
Amarin Receives European Commission (EC) Approval for VAZKEPA to Reduce Cardiovascular Risk GlobeNewswire Inc. - 3/30/2021 6:24:23 AM
Amarin announces clinical recommendations for Vascepa in Canada and Egypt Seeking Alpha - 3/29/2021 10:33:15 AM
Fifteen Medical Societies Now Recommend Icosapent Ethyl to Reduce Cardiovascular Risk, Further Supporting that VASCEPA® is R... GlobeNewswire Inc. - 3/29/2021 7:00:00 AM
Nextech AR (OTCQB: NEXCF) Doubling Sales - Emerging Growth Report InvestorsHub NewsWire - 3/24/2021 6:45:37 AM
HLS Therapeutics highlights promising VASCEPA data analysis Seeking Alpha - 3/17/2021 11:55:39 AM
VASCEPA® (Icosapent Ethyl) Found in Prespecified and Post Hoc Analyses to Significantly Reduce Stroke in At-Risk Patients in... GlobeNewswire Inc. - 3/17/2021 11:30:00 AM
Amarin Q4 results led by strong Vascepa sales Seeking Alpha - 2/25/2021 9:48:43 AM
MedResCollab   Wednesday, 07/10/19 08:57:56 AM
Re: SocialBoom post# 200730
Post # of 339961 
SocialBoom,

We have actually spent little to no time trying to prove the same Steven Giardino that posted on ihub previously about his views on REDUCE-IT failing and his arguments that were negative on NWBO and their tech is not a member of MRC. We have spent almost all of our energy on the argument itself, including what our research has revealed to us to be the confounded nature of the REDUCE-IT trial, Amarin's frivolous IP covering Vascepa and its uses, and the out of synch risk:reward compared with current market value. It is AMRN longs that are seeking to slide around and look past these arguments that are focusing on who is making the argument. That is of course a very common logical fallacy, that those who want AMRN to "make them rich" unconsciously commit to help enable them to ignore the content of our research.

Regards,
-MRC


...
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences